AMCA | 502632-11-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: AMCA
• 英文别名: 7-Amino-4-methyl-3-coumarinylacetamide；2-(7-amino-4-methyl-2-oxochromen-3-yl)acetamide
• CAS: 502632-11-3
• 化学式: C₁₂H₁₂N₂O₃
• 分子量: 232.239
• InChiKey: DVWXWTPHKDYFBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  95.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  在 severe acute respiratory syndrome coronavirus main protease 、 2-吗啉乙磺酸 作用下， 以 水 为溶剂， 生成 AMCA 、 Ac-TSAVLQ-OH
  参考文献：
  名称：

  通过动态连接筛选对非肽类蛋白酶抑制剂的抑制片段进行敏感检测和迭代开发。

  摘要：

  A potential anti‐SARS drug has been developed by dynamic ligation screening (DLS), by which nucleophilic fragments are directed to the protein's active site by reversible reaction with an aldehyde inhibitor. Their inhibitory effect is detected by competition with a fluorogenic enzyme substrate. With this concept, low‐affinity fragments binding specifically to the active site are quickly identified in a functional enzyme assay.

  DOI：

  10.1002/anie.200704594

文献信息

• Fibroblast activation protein inhibitor compounds and methods
  申请人：Cohen Frederick

  公开号：US20060276435A1

  公开（公告）日：2006-12-07

  Amino terminus-blocked peptide boronate compounds of Formulas I and II are useful for inhibiting Fibroblast Activation Protein (FAP) and other proteases, and for treating disorders mediated by FAP. Methods of using the amino terminus blocked peptide boronate compounds, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式 I 和 II 的氨基末端阻断肽硼酸化合物可用于抑制成纤维细胞活化蛋白（FAP）和其他蛋白酶，并用于治疗由FAP介导的疾病。公开了使用氨基末端阻断肽硼酸化合物以及其立体异构体、互变异构体、溶剂合物和药用可接受的盐来进行体外、原位和体内对哺乳动物细胞中的这些疾病进行诊断、预防或治疗的方法，或相关的病理状况。
• Fibroblast Activation Protein Inhibitor Compounds and Methods
  申请人：Cohen Frederick

  公开号：US20080280856A1

  公开（公告）日：2008-11-13

  Amino terminus-blocked peptide boronate compounds of Formulas I and II are useful for inhibiting Fibroblast Activation Protein (FAP) and other proteases, and for treating disorders mediated by FAP. Methods of using the amino terminus blocked peptide boronate compounds, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  I和II式的氨基端阻断肽硼酸化合物可用于抑制成纤维细胞活化蛋白（FAP）和其他蛋白酶，并用于治疗由FAP介导的疾病。本文披露了使用氨基端阻断肽硼酸化合物及其立体异构体、互变异构体、溶剂化物和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
• Synthesis of Drug Conjugates Via Reaction With Epoxide-Containing Linkers
  申请人：UNIVERSITY OF SOUTHERN CALIFORNIA

  公开号：US20130203998A1

  公开（公告）日：2013-08-08

  The present invention relates to drug derivatives and linkers. The invention specifically relates to compounds and methods of phosphonates and linkers, that are useful as carriers for imaging agents and useful in the treatment of various bone diseases.

  本发明涉及药物衍生物和连接剂。本发明特别涉及磷酸酯和连接剂的化合物和方法，这些化合物在成像剂的载体中有用，并在治疗各种骨疾病中有用。
• Combinatorial protease substrate libraries
  申请人：IRM, LLC

  公开号：US20030059847A1

  公开（公告）日：2003-03-27

  Non-peptide protease substrate libraries and high purity protease substrate libraries are constructed, e.g., using fluorogenic compounds. The libraries are useful in obtaining substrate profiles for a variety of proteases, such as methods for determining both prime and non-prime protease recognition sequences.

  非肽蛋白酶底物库和高纯度蛋白酶底物库的构建，例如使用含氟化合物。这些文库可用于获得各种蛋白酶的底物图谱，如确定蛋白酶识别序列的质点和非质点的方法。
• Modulators of transmembrane protease serine 6
  申请人：Harris Jennifer

  公开号：US20050054027A1

  公开（公告）日：2005-03-10

  This invention provides novel methods for identifying modulators of transmembrane protease serine 6 (TMPRSS6). The methods comprise screening test agents for ability to modulate proteolysis of a pathogenic toxin substrate or a synthetic peptide substrate of TMPRSS6. The methods can further comprise screening the identified modulating agents for ability to inhibit infections of pathogens. Also provided in the invention are methods and pharmaceutical compositions for treating infections of pathogens whose toxins are proteolytically activated by TMPRSS6.

  本发明提供了鉴定跨膜丝氨酸蛋白酶 6（TMPRSS6）调节剂的新方法。这些方法包括筛选调节致病毒素底物或 TMPRSS6 合成肽底物的蛋白分解能力的试验制剂。该方法还包括筛选出的调节剂抑制病原体感染的能力。本发明还提供了治疗病原体感染的方法和药物组合物，这些病原体的毒素被TMPRSS6蛋白水解激活。